TG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's Fast 500 and Raising Revenue Outlook [Yahoo! Finance]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Yahoo! Finance
The recognition underscores the meteoric rise of BRIUMVI, its breakthrough treatment for relapsing multiple sclerosis, approved in late 2022. CEO Michael S. Weiss lauded the team's efforts and emphasized the company's commitment to advancing treatment options for multiple sclerosis patients, a sentiment echoed by its 230% year-over-year growth in Q3 2024 revenue. Warning! GuruFocus has detected 8 Warning Signs with TGTX. Fueled by robust market uptake, TG Therapeutics reported $83.3 million in Q3 2024 U.S. BRIUMVI revenuea 15% increase from the previous quarterand raised its full-year revenue guidance to $300305 million. With over 92% of patients showing no disability progression after five years, BRIUMVI continues to redefine therapeutic benchmarks. The company's innovative pipeline, including a subcutaneous version of BRIUMVI and novel CAR-T cell therapies, signals its intent to dominate the autoimmune treatment landscape. Investors are taking notice as TG Therapeutics combine
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™GlobeNewswire
- Deloitte Unveils 2024 North America Technology Fast 500™ Rankings [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks To Explore This November 2024 [Yahoo! Finance]Yahoo! Finance
- Exploring Three High Growth Tech Stocks For Future Potential [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 11/4/24 - Miss
TGTX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- 11/12/24 - Form 4
- TGTX's page on the SEC website